Abstract
Etoricoxib is one of the most popular representatives of a group of nonsteroidal anti-inflammatory drugs (NSAIDs), which is widely used in Russia and other countries of the world. It is a highly selective cyclooxygenase 2 inhibitor that has a rapid and pronounced analgesic effect, a high antiinflammatory potential, and an ability to affect the development of central sensitization, one of the central mechanisms for chronic pain. The therapeutic potential and safety of etoricoxib have been extensively tested in numerous large-scale randomized controlled trials (RCTs). It has proven to be an effective agent for relief of acute pain (including that in dental practice) and acute gouty arthritis, for long-term treatment of rheumatoid arthritis, ankylosing spondylitis (AS), and osteoarthritis (OA). A meta-analysis of a series of RCTs suggests that etoricoxib may be a more effective analgesic drug for AS and OA than other NSAIDs. Etoricoxib significantly less frequently cause gastrointestinal complications than non-selective NSAIDs. The cardiovascular risk associated with etoricoxib is not higher than that with non-selective NSAIDs such as diclofenac.
Highlights
Etoricoxib is one of the most popular representatives of a group of nonsteroidal anti-inflammatory drugs (NSAIDs), which is widely used in Russia and other countries of the world
The therapeutic potential and safety of etoricoxib have been extensively tested in numerous large-scale randomized controlled trials (RCTs)
It has proven to be an effective agent for relief of acute pain and acute gouty arthritis, for long-term treatment of rheumatoid arthritis, ankylosing spondylitis (AS), and osteoarthritis (OA)
Summary
Риск развития кардиоваскулярных катастроф при использовании эторикоксиба не выше, чем на фоне приема неселективных НПВП, таких как диклофенак. Что одним из наиболее эффективных анальгетиков является эторикоксиб: индекс NNT (number needed to treat, число больных, которых надо пролечить для получения отличия от плацебо – ПЛ) для 50% улучшения при использовании этого препарата составил 1,8. Высокая эффективность эторикоксиба как ургентного анальгетика была подтверждена при его использовании для купирования боли после стоматологических операций. [33] провели метаанализ 6 РКИ (n=851), в которых эффективность эторикоксиба сравнивалась с действием ряда других НПВП при данной патологии. При этом в отношении купирования боли эторикоксиб оказался наиболее «сильным»: стандартизированное различие средних (СРС) для этого препарата составило -2,2 (95% ДИ от -3,1 до -1,3). 3. Сравнение эффективности эторикоксиба и других НПВП при АС (метаанализ 26 РКИ, n=3410; адаптировано из [36]) Fig. 3. Efficacy of etoricoxib versus other NSAIDs in patients (n=3410) with AS (meta-analysis of 26 RCTs; adapted from [36])
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
